Background The prevalence of urolithiasis in general Chinese population was 5%>10%. It has been reported as a common complication of gout in many countries (20%>39.5%) but not yet in China. Urolithiasis is one of the contraindications of uricosuric drugs. However, allopurinol, the only other available urate lowering drug in China, has been confirmed high risk of allopurinol hypersensitivity syndrome in Chinese population and those with chronic kidney disease. Objectives To investigate the prevalence of urolithiasis in southern Chinese gout patients and the possible risk factors. Methods 201 hospitalized patients with primary gout were recruited and their clinical data were collected. Current urolithiasis was defined as positive image finding including ultrasound, plain film or computer tomography. Positive history of urolithiasis delivery or urolithiasis surgery but negative image finding was defined as previous urolithiasis. Results (1)Among 201 gout patients, 89.1% were male with mean age 57.5±16.9 years while 10.9% were female with mean age 68.5±11.9 years. The mean disease duration was 7.9±7.4 years with involved joints 6.4±7.4. 30.7% patients presented tophi. The average serum uric acid (sUA) was 8.9±2.7mg/dl with 24h uric acid excretion 451.9±240mg. 91.6% patients excreted uric acid lower than 800mg/24h. Serum creatinine was 133.1±84.6umol/l and estimate glomerular filtration rate (eGFR) 60.0±19.4ml/min. (2) 33.8% patients complicated with urolithiasis, of which 75.0% were current urolithiasis and 33.8% were current urolithiasis without positive urolithiasis history. 84.3% were neprolithiasis and 57.1% were multiple urolithiasis. (3)Table 1 showed significant differences of sUA, hyperuricemia, eGFR, impaired renal function and renal cyst between urolithiasis group and non-urolithaisis group. Current urolithiasis exacerbate eGFR more than previous urolithiasis (51.4±18.3ml/min VS 61.8±17.8ml/min, P=0.045). (4) Urolithiasis was significantly correlated with hyperuricemia (r=0.156, P=0.027), impaired renal function (r=0.27, P<0.001) and renal cyst (r=-0.252, P<0.001). Logistic regression showed that renal cyst negatively predicted the presence of urolithiasis in gout patients (OR=0.066, 95%CI 0.013-0.298, P=0.001) while eGFR<60ml/min promoted urolithiasis (OR=3.786, 95%CI 1.516-9.454, P=0.004). Conclusions Our results showed high prevalence of urolithiasis in southern Chinese gout patients. Routine imaging test on urinary system should be performed to detected urolithiasis in all gout patients especially for those with renal impairment. Disclosure of Interest None Declared
BackgroundWhether the fertile female systemic lupus erythematosus (SLE) patients have low incidence of hyperuricemia like healthy fertile women? There were few reports yet.ObjectivesTo explore the urine acid (UA) level and its influence fators in the fertile female SLE patients.MethodsFertile female SLE patients were recruited as well as healthy fertile women as control. Blood UA concentration were tested and compared. In the SLE group, patients were further divided into two subgroups (high UA subgroup and normal UA subgroup, by 358 μmol/l), and the kidney index, SLE disease indicators, SLEDAI score and blood lipid level were compared between them. To determine the independent factors affecting the UA level of SLE patients, binary logistic regression analysis and multiple linear regression analysis were further applied.Results1.The mean age of the SLE group (n=107) and the control group (n=50) were (28.93±7.98) years and (30.34±5.85) years, with no significant difference (t=-1.142, p<0.05). The median disease duration of the SLE group was (25.64±31.11) months. Only seven SLE patients presented renal failure, and the average CRE level of the SLE group was (87.56±63.26) μmol/l.The average SLEDAI was 7.07±5.86.2.The mean UA concentration of the SLE group and the control group were (367.43±159.86) μmol/l and (296.78±69.87) μmol/l, with remarkable distinction (t=3.852, P<0.001). The incidence of high UA in the SLE group and the control group were 42.06% and 14%, with significant difference (χ2 =12.109, P<0.05).3.16 SLE patients received the medications that may increase the UA level, including azathioprine and cyclosporin. The binary logistic regression analysis indicated that these medications were not the risk factor of high UA in SLE patients (95%CI 0.268–2.389, P>0.05).4.In the high UA subgroup (n=45) of the SLE group, CRE, TG, LDL and HDL were dramatically higher than those of the normal UA subgroup (n=62, t=2.582, 2.941, -2.691, all P<0.05), and C3 was markedly lower than that of the normal UA subgroup (t=-3.225, P<0.05). The positive rates of anti-dsDNA and urine blood of the high UA subgroup were significantly higher than those of the normal UA subgroup (χ2 =7.010, 7.489, both P<0.05).5.The multiple linear regression analysis indicated that CRE, TG, HDL and urine blood were the independent factors for UA level of SLE patients (t=4.383, 3.182, -2.036, 2.692, all P<0.05, table 1).Table 1.Multiple linear regression analysis of variables associated with UA concentrationVariableUnstandardized coefficientsStandardized coefficientstP95%CIBStd. ErrorCRE0.7320.1570.3784.6530.0000.420–1.044TG21.7088.8780.2102.4450.0164.095–39.322LDL1.7400.085HDL−40.73720.006−0.158−2.0360.044−80.423 to −1.051C3−0.7830.435Anti-DNA1.2930.199Urine blood59.01423.4760.2032.5140.01412.445–105.584Constant270.98929.8149.089<0.001211.845–330.132ConclusionsThe fertile female SLE patients showed higher incidence of hyperuricemia than healthy fertile women, and CRE, TG, HDL and urine blood were the independent factors for UA level.Disclosure of Inter...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.